USA - NASDAQ:RENB - US29350E1047 - Common Stock
The current stock price of RENB is 0.1823 USD. In the past month the price decreased by -20.24%. In the past year, price decreased by -63.33%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.44 | 382.39B | ||
AMGN | AMGEN INC | 12.5 | 146.77B | ||
GILD | GILEAD SCIENCES INC | 14.34 | 137.68B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.04 | 100.05B | ||
REGN | REGENERON PHARMACEUTICALS | 12.59 | 60.89B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.44B | ||
ARGX | ARGENX SE - ADR | 80.93 | 45.91B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.7 | 38.76B | ||
INSM | INSMED INC | N/A | 30.47B | ||
NTRA | NATERA INC | N/A | 23.99B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.92B | ||
BIIB | BIOGEN INC | 8.95 | 21.01B |
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 25 full-time employees. The company went IPO on 2014-11-18. The firm is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
LUNAI BIOWORKS INC
2080 Century Park East, Suite 906
Los Angeles CALIFORNIA US
Employees: 25
Phone: 14539179840
The current stock price of RENB is 0.1823 USD. The price decreased by -4.4% in the last trading session.
The exchange symbol of LUNAI BIOWORKS INC is RENB and it is listed on the Nasdaq exchange.
RENB stock is listed on the Nasdaq exchange.
LUNAI BIOWORKS INC (RENB) has a market capitalization of 42.10M USD. This makes RENB a Nano Cap stock.
LUNAI BIOWORKS INC (RENB) currently has 25 employees.
LUNAI BIOWORKS INC (RENB) has a resistance level at 0.22. Check the full technical report for a detailed analysis of RENB support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RENB does not pay a dividend.
LUNAI BIOWORKS INC (RENB) will report earnings on 2025-10-08.
LUNAI BIOWORKS INC (RENB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.44).
The outstanding short interest for LUNAI BIOWORKS INC (RENB) is 0.76% of its float. Check the ownership tab for more information on the RENB short interest.
ChartMill assigns a fundamental rating of 1 / 10 to RENB. While RENB seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months RENB reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 59.96% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -57.15% | ||
ROE | -76.11% | ||
Debt/Equity | 0 |